AIDS Clinical Trial Unit Receives Grant Renewa- Clinical & Research News - For and about the Physicians and Researchers of Brigham and Women's HospitalAIDS Clinical Trial Unit Receives Grant Renewa- Clinical & Research News - For and about the Physicians and Researchers of Brigham and Women's Hospital

Skip to contents

AIDS Clinical Trial Unit Receives Grant Renewal

The Partners/Harvard AIDS Clinical Trials Unit, led by Principal Investigator Dan Kuritzkes, MD, has been granted a seven-year renewal of $7.5 million to continue its efforts in research and treatment. The unit, which includes BWH, MGH and BIDMC, has been a leader in developing anti-HIV therapies.

The Partners/Harvard unit is apart of about 25 domestic and 20 international units that comprise the National Institutes of Health (NIH) group known as the AIDS Clinical Trials Group (ACTG) which is the largest HIV/AIDS clinical trials organization in the world.

Kuritzkes is the director of AIDS Research at BWH and professor of medicine at HMS, and serves as vice chair of the ACTG. Paul Sax, MD, is also a leader of the Partners/Harvard ACTU clinical research site.